Karyopharm EVP granted 32,415 RSUs in Form 4

Karyopharm Therapeutics Inc. executive vice president and chief development officer Stuart Poulton reported an award of 32,415 shares of common stock on January 31, 2026.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive vice president and chief development officer Stuart Poulton reported an award of 32,415 shares of common stock on January 31, 2026. These were granted as restricted stock units under the company’s 2022 Equity Incentive Plan at a price of $0 per share.

The RSUs convert into common stock on a one-for-one basis. Half of the award is scheduled to vest on January 31, 2027, and the remaining half on January 31, 2028. Following this grant, Poulton beneficially owns 99,807 shares of Karyopharm common stock in direct ownership.

Insider Trade Summary

Grant/Award: 32,415 shares

Grant/Award 1 txn

Insider Poulton Stuart

Role EVP, Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,415	$0.00	$0.00

Holdings After Transaction: Common Stock — 99,807 shares (Direct)

Footnotes (1)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Karyopharm (KPTI) report for Stuart Poulton?

Karyopharm reported that EVP and Chief Development Officer Stuart Poulton received 32,415 restricted stock units of common stock. The units were granted at $0 per share and increase his directly owned holdings to 99,807 Karyopharm common shares after the transaction.

When do Stuart Poulton’s new Karyopharm (KPTI) RSUs vest?

Poulton’s restricted stock units vest in two equal installments. Fifty percent of the 32,415 RSUs vest on January 31, 2027, and the remaining 50% vest on January 31, 2028, according to the terms disclosed for this equity award.

What equity plan governed the RSU grant to Karyopharm (KPTI) EVP Stuart Poulton?

The 32,415 restricted stock units granted to Stuart Poulton were issued under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan authorizes equity-based awards that convert into Karyopharm common stock on a one-for-one basis upon vesting.

How many Karyopharm (KPTI) shares does Stuart Poulton own after this Form 4?

After the reported RSU award, Stuart Poulton beneficially owns 99,807 shares of Karyopharm Therapeutics common stock. The filing identifies this ownership as direct, reflecting his holdings following the January 31, 2026 equity grant transaction.

What was the price per share for Stuart Poulton’s new Karyopharm (KPTI) RSUs?

The 32,415 restricted stock units granted to Stuart Poulton were reported at a transaction price of $0 per share. This reflects that the award was a compensatory equity grant rather than an open-market purchase of Karyopharm common stock.

What type of security did Karyopharm (KPTI) grant to Stuart Poulton in this filing?

Karyopharm granted restricted stock units, which convert into common stock on a one-for-one basis. The Form 4 describes these as RSUs linked to Karyopharm common shares, vesting in two equal tranches in 2027 and 2028 under the company’s 2022 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poulton Stuart

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		32,415(1)	A	$0	99,807	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.